Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype and
accounts for approximately 15–20% of breast cancer cases. In this study, we identified …

Triple-negative breast cancer (TNBC) patients commonly exhibit poor prognosis and high
relapse after treatment, but there remains a lack of biomarkers and effective targeted …

Triple-negative breast cancer (TNBC) exhibits the poorest outcomes among breast cancer
subtypes due to the high heterogeneity and a lasting scarcity of effectual treatments …

Triple-negative breast cancer (TNBC) is highly aggressive with very limited treatment
options due to the lack of efficient targeted therapies and thus still remains clinically …

Background The functions of many proteins are tightly regulated with a complex array of
cellular functions including ubiquitination. In cancer cells, aberrant ubiquitination may …

Triple negative breast cancers exhibit very aggressive features and poor patient outcomes.
These tumors are enriched in cancer stem cells and exhibit resistance to most treatments …

Purpose Dexamethasone (Dex), a glucocorticoid (GC), is used as a pretreatment drug in
cancer patients undergoing chemotherapy. Dex functions by binding to the glucocorticoid …

Background Cyclin-dependent kinase 7 (CDK7) is crucial for cell cycle progression and
gene expression transcriptional regulation, which are often not assessed in cancer …

Targeted therapy for triple-negative breast cancers (TNBC) remains a clinical challenge due
to tumour heterogeneity. Since TNBC have key features of transcriptionally addicted …

Triple-negative breast cancer (TNBC) is more difficult to treat and has a higher mortality rate
than other subtypes. Although hormone receptor-targeted therapy is an effective treatment to …